Abstract
We report two cases with macroprolactinoma who during medical treatment with bromocriptine showed a normalization of PRL levels and a reduction of tumor size as documented by computed tomography. After a few months of therapy both patients suddenly complained of worsening of their visual fields and a computed tomography demonstrated a reenlargement of the tumor mass; whereas in one patient PRL levels remained always within normal range, in the other patient, who was taking spiramycin for an intercurrent illness, there was also an escape of the hormonal secretion from the inhibitory effect of bromocriptine. The first patient underwent surgery, whereas in the second patient continuation of bromocriptine and interruption of antibiotic treatment resulted in progressive improvement in visual fields and a reduction of tumor size again. We want to stress that in patients with macroprolactinomas responsive to the medical treatment both in terms of PRL secretion and of tumor size reduction, an escape from the effects of bromocriptine, although infrequently, may occur.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Eversmann T., Fahlbusch R., Rjosk H.K., Von Werder K. Persisting suppression of PRL secretion after long-term treatment with bromocriptine in patients with prolac tinoma. Acta Endocrinol. (Kbh.) 92: 413, 1979.
Von Werder K., Fahlbusch R., Landgraf R., Pickard C., Rjosk H., Scriba P. Treatment of patients with prolactinoma. J. Endocrinol. Invest. 1: 47, 1978.
Chiodini P.G., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G.P., Luccarelli G., Rainer E., Horowsky R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 53: 737, 1981.
Thorner M.O., Perryman R.L., Rogol A.D., Conway B.P., MacLeod R.M., Login I.S., Morris J.L. Rapid changes of prolactinoma volume following withdrawal and restitution of bromocriptine. J. Clin. Endocrinol. Metab. 53: 480, 1981.
Mohanty S., Tandon P.N., Banerji A.K., Prakash B. Haemorrhage into pituitary adenomas. J. Neurol. Neurosurg. Psychiatry 40: 987, 1977.
Clark B.J., Fluckiger E., Loew D.M., Vigouret J.M. How does bromocriptine work? Triangle 17: 21, 1978.
Dastur H.M., Pandya S.K. Haemorrhagic adenomas of pituitary gland, their clinical and radiological presentation and treatment. Neurology (India) 19:4, 1971.
Muller W.I., Pia H.W. Zur Klinik und Aetiologie der Massenblutungen in Hypophysenadenome. Deutsche Zeitsschrift für Nervenheilkunde 170: 326, 1953.
Poppen J.L. Chromophobe pituitary adenoma. Current concepts of diagnosis and treatment. Postgrad. Med. 40: 396, 1966.
Azria M., Kieckel J.R., Lavene D. Contribution a l’étude de l’interaction de la triacetylo-leandomycine avec l’ergotamine ou la dihydroergotamine. J. Pharmacol. 70:431, 1979.
Schwinn G., Dirks H., Me Intosh C., Kobbérling J. Metabolie and clinical studies on patients with acromeg aly treated with bromocriptine over 22 months. Eur. J. Clin. Invest. 7: 101, 1977.
Author information
Authors and Affiliations
Additional information
Supported by Grant no 810139296 of CNR.
Rights and permissions
About this article
Cite this article
Dallabonzana, D., Spelta, B., Oppizzi, G. et al. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 6, 47–50 (1983). https://doi.org/10.1007/BF03350560
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350560